| Therapy | Indication | Sites | Status | NCT# | Trial Name | IRCT |
|---|---|---|---|---|---|---|
| NK Cell Therapy | Glioma, Glioblastoma Multiforme, High Grade Glioma (III or IV) | Rasoul Akram Hospital, Tehran, Iran | Recruiting Phase II | NCT06687681 | Injection of Active Allogeneic Natural Killer Cells in Patients with Gliomas | IR.ACECR.ROYAN.REC.1402.001 IRCT20170122032121N7 |
| NK Cell Therapy | Recurrent, Refractory Neuroblastoma | Rasoul Akram Hospital, Tehran, Iran | Recruiting Phase I | NCT06674265 | Safety and Efficacy of Systemic Allogeneic NK Cells in Refractory/Recurrent High-risk Neuroblastoma | IR.ACECR.ROYAN.REC.1403.032 IRCT20170122032121N8 |
| NK Cell Therapy | Recurrent Glioblastoma Multiforme Patients | Royan Institute, Tehran, Iran | Completed Phase I | Pending | NK Cell Therapy for Recurrent Glioblastoma Multiforme Patients | IR.ACECR.ROYAN.REC.1400.077 IRCT20170122032121N6 |
| NK Cell Therapy | Recurrent malignant brain tumors | Children’s Medical Center Hospital, Tehran, Iran | Completed Phase I | NCT05108012 | Intra-lesion Injection of Activated Natural Killer (NK) Cells in Recurrent Malignant Brain Tumors | IR.ACECR.ROYAN.REC.1398.261 IRCT20170122032121N5 |